Selected studies BPC-157 and growth hormone receptor expression in tendon fibroblasts (Molecules, 2014) PubMed | PMID 25415472 BPC-157 and angiogenesis in muscle and tendon healing research (J Physiol Pharmacol, 2009) PubMed | PMID 20388964 BPC-157 and the Src-Caveolin-1-eNOS vasomotor pathway research (Sci Rep, 2020) PubMed | PMID 33051481 BPC-157 and gastric ulcer research in rats (World J Gastroenterol, 2004) PubMed | PMID 15052688 Browse all BPC-157 research on PubMed PubMed Literature Search Cited literature is provided for scientific reference only
Before adding supplements, foods, or sweat practices, the first move is to address the environment
Free 5 cases of HUMANITEA to be delivered upon request
Start low, go slow For any new peptide: Start at lowest effective dose Assess tolerance for 1-2 weeks Increase gradually if needed Don't rush to maximum dose Example progression: BPC-157: Start 250mcg 2x daily, can increase to 500mcg 2x daily if needed CJC/Ipa: Start 200mcg each, can increase to 300mcg if no sides Monitor for side effects Common across peptides: Injection site reactions (redness, swelling) Headaches (especially GH peptides initially) Water retention (GH peptides, GLP-1s) Nausea (GLP-1s, Melanotan II) When to stop: Severe allergic reaction (hives, difficulty breathing) Persistent severe side effects Unexplained symptoms Lack of improvement after reasonable trial Get baseline and follow-up bloodwork Before starting peptides: Basic metabolic panel Liver and kidney function Thyroid panel Relevant hormones (testosterone, IGF-1, etc.) During use: Follow-up testing every 3-4 months Monitor markers relevant to your peptides Adjust protocols based on results Legal and regulatory awareness Understand status: FDA-approved peptides require prescription Research peptides are gray area (legal to possess, not approved for human use) Athletic drug testing includes most peptides (WADA banned) See our are peptides legal guide for complete regulatory information
Our body naturally produces glutathione, but levels decrease significantly as we age
A review of an investigational drug retatrutide, a novel triple agonist agent for the treatment of obesity
